UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________

FORM 8-K

_________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~February 2026, 2026

_________________________________________________________

Crinetics Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

_________________________________________________________


Delaware	001-38583	26-3744114
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6055 Lusk Boulevard
San Diego, California		92121
(Address of Principal Executive Offices)		(Zip Code)


Registrant’s Telephone Number, Including Area Code: (858) 450-6464

(Former Name or Former Address, if Changed Since Last Report)

_________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

CRNX

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5 2.02 ~~Departure~~ ofResults ~~Directors or Certain Officers; Election~~ of ~~Directors,~~Operations ~~Appointment~~and ofFinancial ~~Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

On ~~January 20~~February 26, 2026, ~~the board of directors of~~ Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) ~~approved~~issued a ~~change~~press inrelease ~~title~~reporting ~~and~~its ~~responsibilities~~financial results for ~~Jeff~~the ~~Knight,~~period ~~from~~ended ~~Chief~~December 31, ~~Operating~~2025. ~~Officer~~The tofull ~~Chief~~text ~~Development~~of ~~and~~the ~~Operating~~press ~~Officer,~~release ~~effective~~is ~~January~~attached 2,as ~~2026~~Exhibit 99.1 to this Current Report on Form 8-K.

~~The~~In ~~change~~accordance inwith ~~title~~General ~~reflects~~Instruction MrB.2 ~~Knight's~~of ~~responsibilities~~Form ~~and~~8-K, ~~scope~~the ofinformation ~~duties~~contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

There were no changes to Mr. Knights's compensation arrangements, as described in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 23, 2025 (the "2025 Proxy Statement"), in connection with this title change. There are no arrangements or understandings between Mr. Knight and any other person pursuant to which he was selected as Chief Development and Operating Officer, there are no family relationships between Mr. Knight and any director or executive officer of the Company, and there are no reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving Mr. Knight and the Company. A description of Mr. Knight's business experience is contained in the 2025 Proxy Statement, which description is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.						Description
99.1						Press Release dated February 26, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned ~~thereunto~~hereunto duly authorized.

			Crinetics Pharmaceuticals, Inc.
Date:	~~January~~February 26, 2026	By:	/s/ R. Scott Struthers, Ph.D.
			R. Scott Struthers, Ph.D.President and Chief Executive Officer(Principal Executive Officer)

Filing Compare · Crinetics Pharmaceuticals, Inc.